Phase 3
N=76
13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF
Acute Liver Failure
Bottom Line
View on ClinicalTrials.gov: NCT02786836 ↗Enrolled (actual)
76
Serious AEs
45.2%
Results posted
Dec 2020
Primary outcome: Primary: Peak Percent Dose Recovery (PDR) Value — 10.2; 1.9 percentage per hour
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- 13C-Methacetin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Texas Southwestern Medical Center
- Primary completion
- Sep 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Peak Percent Dose Recovery (PDR) Value |
9.1; 2.3 | — |
| SECONDARY Peak Percent Dose Recovery (PDR) Value |
9.1; 2.3 | — |
| SECONDARY Cumulative Percent Dose Recovery 20 (cPDR20) Value |
1.4; 0.2 | — |
Summary
The ALFSG-MBT protocol is for a multicenter, open label, non-randomized study to determine the value of Breath Identification® (BreathID®) N-(4-Methoxy-13C-phenyl)acetamide (13C-Methacetin) Breath Test System in predicting the outcome of patients diagnosed with severe acute liver injury that is not related to acetaminophen overdose or acute liver failure who meet inclusion/exclusion criteria.
Up to 200 evaluable patients will be enrolled. An evaluable patient is one who has completed one or more breath tests for at least 30 minutes after administration of the 13C-Methacetin solution (test substrate).
The Breath Test will be performed up to five times during the study period on all enrolled patients. The first Breath Test will be performed upon admission into the study (Day 1) and repeated on Days 2, 3, 5 and 7 provided no contra-indications are present. Each test continuously measures changes in the metabolism of the 13C-Methacetin in order to assess the improvement or deterioration in liver metabolic function about improvement or deterioration in liver metabolic function. If an enrolled non-APAP ALI or ALF patient receives a liver transplant, is discharged /transferred from the hospital or dies prior to Day 7, additional Breath Tests will not be performed.
Patients will be contacted for the Day 21 follow up (21 days after enrollment into the trial) to determine spontaneous survival, transplantation and occurrence of serious adverse events since the patient's last study treatment.
Eligibility Criteria
Inclusion Criteria
- Adult men or women (18-80 years of age)
- Severe acute liver injury not related to acetaminophen overdose: INR ≥2.0; no evidence of HE
- Acute liver failure: INR ≥1.5; presence of any degree of HE
- Duration of illness 15 µg/kg/min dopamine, >0.1 µg/kg/min epinephrine, or >0.1 norepinephrine µg/kg/min
- Extensive small bowel resection (>50 cm)
- Any evidence of upper GI bleeding at enrollment requiring intervention (endoscopy or red blood cell (RBC) transfusion specifically for upper GI bleeding)
- Liver transplantation (LT) prior to enrollment. (Note: Listing for LT does not preclude participation in the trial.)
- Pregnancy or breastfeeding women (Note: Pregnancy related non-APAP ALI or ALF may be considered for entry following the delivery of the baby and assuming the mother does not wish to breastfeed or collect breast milk during the study period.)
- Allergic to acetaminophen (such as Tylenol® or any other acetaminophen-containing medications)
- Participation in other clinical studies evaluating other experimental treatments or procedures. (Note: Participation in observatory studies is not an exclusion.)
- Patients in whom enteral drugs or fluids are contra-indicated or the patient either does not have an appropriately placed naso-enteric/orogastric tube in situ or cannot tolerate taking the drug preparation orally (200 ml)
- Budd-Chiari Syndrome
- Non-APAP ALI or ALF caused by malignancy
- Moderate and severe adult respiratory distress syndrome (ARDS), as defined by Berlin Criteria.
- Subjects who have received amiodarone in the 30 days prior to study enrollment
- Consumption of any food or beverage that contains caffeine in the 24 hours prior to enrollment
- Consumption of any of the following drugs that may interfere with the metabolism of 13C-Methacetin in the 48 hours prior to study enrollment including: allopurinol, carbamazepine, cimetidine, ciprofloxacin, daidzein, disulfiram, Echinacea, enoxacin, fluvoxamine, methoxsalen, mexiletine, montelukast, norfloxacin, phenylpropanolamine, phenytoin, propafenone, rifampin, terbinafine, ticlopidine, thiabendazole, verapamil, zileuton or oral contraceptives
- Consumption of alcohol in the 24 hours prior to enrollment
- Smoking cigarettes in the 8 hours prior to enrollment.
Data sourced from ClinicalTrials.gov (NCT02786836). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.